Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
13 Jan 2022
Historique:
received: 29 11 2021
accepted: 09 01 2022
entrez: 21 1 2022
pubmed: 22 1 2022
medline: 4 2 2022
Statut: epublish

Résumé

Peritoneal metastases are the leading cause of morbidity and mortality in ovarian cancer. Cancer cells float in peritoneal fluid, named ascites, together with a definitely higher number of non neo-neoplastic cells, as single cells or multicellular aggregates. The aim of this work is to uncover the features that make these aggregates the metastasizing units. Immunofluorescence revealed that aggregates are made almost exclusively of ovarian cancer cells expressing the specific nuclear PAX8 protein. The same cells expressed epithelial and mesenchymal markers, such as EPCAM and αSMA, respectively. Expression of fibronectin further supported a hybrid epithelia-mesenchymal phenotype, that is maintained when aggregates are cultivated and proliferate. Hematopoietic cells as well as macrophages are negligible in the aggregates, while abundant in the ascitic fluid confirming their prominent role in establishing an eco-system necessary for the survival of ovarian cancer cells. Using ovarian cancer cell lines, we show that cells forming 3D structures neo-expressed thoroughly fibronectin and αSMA. Functional assays showed that αSMA and fibronectin are necessary for the compaction and survival of 3D structures. Altogether these data show that metastasizing units display a hybrid phenotype that allows maintenance of the 3D structures and the plasticity necessary for implant and seeding into peritoneal lining.

Identifiants

pubmed: 35055018
pii: ijms23020833
doi: 10.3390/ijms23020833
pmc: PMC8775835
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ricerca Corrente Ministero Salute 2021 to MFDR
Organisme : FPRC 5xmille Ministero Salute 2015 "Strategy" to MFDR

Références

Biochim Biophys Acta. 2013 Oct;1830(10):4885-97
pubmed: 23811340
PLoS One. 2013 Sep 09;8(9):e73341
pubmed: 24039918
J Clin Invest. 2014 Jun;124(6):2611-25
pubmed: 24762435
Animal Model Exp Med. 2021 Mar 23;4(2):138-150
pubmed: 34179721
Nat Rev Cancer. 2019 Dec;19(12):716-732
pubmed: 31666716
Pathol Res Pract. 2018 Oct;214(10):1564-1571
pubmed: 30082157
Am J Surg Pathol. 2010 May;34(5):627-35
pubmed: 20414098
Asian Pac J Cancer Prev. ;18(3):667-671
pubmed: 28440973
Mol Oncol. 2020 Sep;14(9):2142-2162
pubmed: 32533757
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
J Clin Invest. 2014 Oct;124(10):4614-28
pubmed: 25202979
Sci Rep. 2018 Aug 24;8(1):12724
pubmed: 30143682
JCI Insight. 2016 Jul 7;1(10):
pubmed: 27482544
Endocr Relat Cancer. 2016 Mar;23(3):147-59
pubmed: 26647384
Cancers (Basel). 2020 May 15;12(5):
pubmed: 32429240
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
Oncogene. 2018 Sep;37(37):5127-5135
pubmed: 29789717
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
J Clin Invest. 2016 Nov 1;126(11):4157-4173
pubmed: 27721235
Nat Rev Cancer. 2013 Apr;13(4):273-82
pubmed: 23426401
Br J Cancer. 2020 Jul;123(1):9-16
pubmed: 32382112
Nat Med. 2020 Aug;26(8):1271-1279
pubmed: 32572264
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):E4978-86
pubmed: 24297935
Oncogene. 2017 Oct 19;36(42):5840-5851
pubmed: 28628116
Gynecol Oncol. 2012 Dec;127(3):595-600
pubmed: 22940488
Clin Exp Metastasis. 2016 Dec;33(8):839-852
pubmed: 27612856
J Exp Med. 2019 Mar 4;216(3):688-703
pubmed: 30710055
Cancer Discov. 2011 Jul;1(2):144-57
pubmed: 22303516
Gynecol Oncol. 2009 Apr;113(1):143-8
pubmed: 19135710
Cancer Biol Ther. 2010 May 15;9(10):764-77
pubmed: 20234191
Sci Rep. 2020 Dec 3;10(1):21018
pubmed: 33273492
Cancer Cell. 2013 Dec 9;24(6):751-65
pubmed: 24332043
Oncotarget. 2016 Jan 5;7(1):712-28
pubmed: 26625210
J Clin Med. 2020 May 16;9(5):
pubmed: 32429448
PLoS One. 2012;7(10):e46858
pubmed: 23056490
J Exp Med. 2020 Apr 6;217(4):
pubmed: 31951251
Nat Genet. 2016 Jul;48(7):758-67
pubmed: 27182968
Am J Clin Pathol. 2002 May;117(5):745-50
pubmed: 12090423
Am J Surg Pathol. 2011 Jun;35(6):816-26
pubmed: 21552115
Cancers (Basel). 2019 Dec 06;11(12):
pubmed: 31817625
Am J Pathol. 2010 Sep;177(3):1053-64
pubmed: 20651229
Mol Oncol. 2019 Feb;13(2):185-201
pubmed: 30353652
Oncogene. 2017 Jun 15;36(24):3384-3396
pubmed: 28114283
Int J Mol Med. 2019 Dec;44(6):2245-2255
pubmed: 31638162

Auteurs

Sonia Capellero (S)

Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
Department of Oncology, University of Torino, 10129 Torino, Italy.

Jessica Erriquez (J)

Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.

Chiara Battistini (C)

Unit of Gynaecological Oncology Research, European Institute of Oncology, IRCCS, 20100 Milan, Italy.

Roberta Porporato (R)

Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.

Giulia Scotto (G)

Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
Department of Oncology, University of Torino, 10129 Torino, Italy.

Fulvio Borella (F)

Gynecology and Obstetrics 1, Department of Surgical Sciences, City of Health and Science, University of Turin, 10100 Turin, Italy.

Maria F Di Renzo (MF)

Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
Department of Oncology, University of Torino, 10129 Torino, Italy.

Giorgio Valabrega (G)

Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
Department of Oncology, University of Torino, 10129 Torino, Italy.

Martina Olivero (M)

Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
Department of Oncology, University of Torino, 10129 Torino, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH